The Collaboration for TB Vaccine Discovery (CTVD) 2nd Annual meeting was held June 23 and 24, 2016 at the Bill & Melinda Gates Foundation Seattle campus. It was a collaborative and productive meeting with 107 participants from academia, independent research institutes, industry, funding organizations and the Gates Foundation. During the first day, experts discussed critical advances in the TB vaccine space over the last year, lessons learned from vaccinology efforts in other infectious diseases, and updates from some of the Gates-funded investments including the CMV-TB vaccine candidate. Gates foundation Global Health President,
Trevor Mundel, also talked about the Global Health division funding priorities and Gates Program Director for TB,
Gilla Kaplan, discussed the funding priorities of the TB program. For the second day, the different CTVD research communities shared their outputs for the first year - the DURT (Donor Unrestricted T cells) group has a plan to analyze human DURT response to BCG vaccination, the NHP (non-human primates) group has started working together to standardize the use of PET-CT as an outcome and the WCV (whole cell vaccines) group has a
review article published in the Journal of Infectious Diseases. CTVD’s aim for the first year was to start small, achieve primary goals (i.e. consolidate membership, launch research communities) and grow. From 20 member institutions in 2015, CTVD now has over 40
members from the US, Europe, Africa, Latin America, and Asia.